HK1209672A1 - Treatment of multiple sclerosis with combination of laquinimod and fampridine - Google Patents
Treatment of multiple sclerosis with combination of laquinimod and fampridineInfo
- Publication number
- HK1209672A1 HK1209672A1 HK15110240.0A HK15110240A HK1209672A1 HK 1209672 A1 HK1209672 A1 HK 1209672A1 HK 15110240 A HK15110240 A HK 15110240A HK 1209672 A1 HK1209672 A1 HK 1209672A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fampridine
- laquinimod
- treatment
- combination
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670758P | 2012-07-12 | 2012-07-12 | |
PCT/US2013/050001 WO2014011827A1 (en) | 2012-07-12 | 2013-07-11 | Treatment of multiple sclerosis with combination of laquinimod and fampridine |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209672A1 true HK1209672A1 (en) | 2016-04-08 |
Family
ID=49914160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110240.0A HK1209672A1 (en) | 2012-07-12 | 2015-10-19 | Treatment of multiple sclerosis with combination of laquinimod and fampridine |
Country Status (16)
Country | Link |
---|---|
US (2) | US20140017226A1 (sl) |
EP (1) | EP2872217A4 (sl) |
JP (1) | JP2015522077A (sl) |
KR (1) | KR20150038072A (sl) |
CN (1) | CN104582793A (sl) |
AR (1) | AR091724A1 (sl) |
AU (1) | AU2013290181A1 (sl) |
BR (1) | BR112015000616A2 (sl) |
CA (1) | CA2873229A1 (sl) |
EA (1) | EA201590191A1 (sl) |
HK (1) | HK1209672A1 (sl) |
IL (1) | IL236230A0 (sl) |
MX (1) | MX2015000485A (sl) |
TW (1) | TW201408300A (sl) |
UY (1) | UY34896A (sl) |
WO (1) | WO2014011827A1 (sl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201404214QA (en) | 2012-02-03 | 2014-08-28 | Teva Pharma | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
US20160046582A1 (en) | 2013-03-14 | 2016-02-18 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
SG11201608674UA (en) * | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726339D0 (en) * | 1997-12-13 | 1998-02-11 | Zeneca Ltd | Human-derived tissue-specific potassium channel |
US20090082471A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
AU2009291781A1 (en) * | 2008-09-10 | 2010-03-18 | Acorda Therapeutics, Inc. | Methods of using sustained release aminopyridine compositions |
ES2548999T3 (es) * | 2009-06-19 | 2015-10-22 | Teva Pharmaceutical Industries Ltd. | Tratamiento de la esclerosis múltiple con laquinimod |
EP2766020A4 (en) * | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
-
2013
- 2013-07-09 UY UY0001034896A patent/UY34896A/es not_active Application Discontinuation
- 2013-07-10 TW TW102124792A patent/TW201408300A/zh unknown
- 2013-07-10 AR ARP130102454 patent/AR091724A1/es unknown
- 2013-07-11 JP JP2015521792A patent/JP2015522077A/ja active Pending
- 2013-07-11 EA EA201590191A patent/EA201590191A1/ru unknown
- 2013-07-11 CN CN201380037036.0A patent/CN104582793A/zh active Pending
- 2013-07-11 KR KR1020157003858A patent/KR20150038072A/ko not_active Application Discontinuation
- 2013-07-11 AU AU2013290181A patent/AU2013290181A1/en not_active Abandoned
- 2013-07-11 WO PCT/US2013/050001 patent/WO2014011827A1/en active Application Filing
- 2013-07-11 CA CA2873229A patent/CA2873229A1/en not_active Abandoned
- 2013-07-11 EP EP13816075.9A patent/EP2872217A4/en not_active Withdrawn
- 2013-07-11 BR BR112015000616A patent/BR112015000616A2/pt not_active IP Right Cessation
- 2013-07-11 MX MX2015000485A patent/MX2015000485A/es unknown
- 2013-07-11 US US13/939,306 patent/US20140017226A1/en not_active Abandoned
-
2014
- 2014-12-14 IL IL236230A patent/IL236230A0/en unknown
-
2015
- 2015-10-19 HK HK15110240.0A patent/HK1209672A1/xx unknown
-
2016
- 2016-04-21 US US15/135,280 patent/US20160235735A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2015000485A (es) | 2015-04-08 |
BR112015000616A2 (pt) | 2017-06-27 |
KR20150038072A (ko) | 2015-04-08 |
JP2015522077A (ja) | 2015-08-03 |
AR091724A1 (es) | 2015-02-25 |
CN104582793A (zh) | 2015-04-29 |
UY34896A (es) | 2014-02-28 |
TW201408300A (zh) | 2014-03-01 |
US20160235735A1 (en) | 2016-08-18 |
CA2873229A1 (en) | 2014-01-16 |
US20140017226A1 (en) | 2014-01-16 |
EP2872217A4 (en) | 2016-03-16 |
EA201590191A1 (ru) | 2015-06-30 |
IL236230A0 (en) | 2015-01-29 |
AU2013290181A1 (en) | 2015-02-26 |
WO2014011827A1 (en) | 2014-01-16 |
EP2872217A1 (en) | 2015-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
HK1209736A1 (en) | N-substituted benzamides and methods of use thereof n- | |
IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
ZA201502503B (en) | Hppd variants and methods of use | |
HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
ZA201401217B (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
GB201217296D0 (en) | Method of treatment and/or prevention | |
EP2852397A4 (en) | HUWENTOXIN IV VARIANTS AND METHODS OF USE | |
HK1218254A1 (zh) | 用拉喹莫德治療多發性硬化症 | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
HK1223855A1 (zh) | 拉喹莫德和氟吡汀組合物用於治療多發性硬化症 | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
HK1227691A1 (zh) | 利用拉喹莫德和特立氟胺的組合來治療多發性硬化症 |